SEC Comment Letter 0000000000-24-003960 to bioAffinity Technologies, Inc. (BIAF)
bioAffinity Technologies, Inc.
Date: April 11, 2024 · CIK: 0001712762 · Accession: 0000000000-24-003960
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-278512
Letter
United States securities and exchange commission logo April 11, 2024 Maria Zannes Chief Executive Officer bioAffinity Technologies, Inc. 22211 W Interstate 10 Suite 1206 San Antonio, TX 78257 Re:bioAffinity Technologies, Inc. Registration Statement on Form S-1 Filed April 4, 2024 File No. 333-278512 Dear Maria Zannes: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Benjamin Richie at 202-551-7857 with any questions. Sincerely, Division of Corporation Finance Office of Industrial Applications and Services cc: Leslie Marlow
Show Raw Text
United States securities and exchange commission logo
April 11, 2024
Maria Zannes
Chief Executive Officer
bioAffinity Technologies, Inc.
22211 W Interstate 10 Suite 1206
San Antonio, TX 78257
Re:bioAffinity Technologies, Inc.
Registration Statement on Form S-1
Filed April 4, 2024
File No. 333-278512
Dear Maria Zannes:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Benjamin Richie at 202-551-7857 with any questions.
Sincerely,
Division of Corporation Finance
Office of Industrial Applications and
Services
cc: Leslie Marlow